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Abstract: The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help fight against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Bamlanivimab is a SARS-CoV-2 monoclonal antibody that is administered as an intravenous infusion
to ambulatory patients with mild or moderate COVID-19, but a concern that arose was deciding the
optimal location for patients to receive the medication. This report describes the development and
implementation of a bamlanivimab infusion center in the emergency department of three hospitals in
Orange County, California, shortly after bamlanivimab received emergency use authorization. As a
result, a total of 601 patients received bamlanivimab in one of these three emergency departments
between December 2020 to April 2021. The emergency department was shown to be an optimal
setting for administration of bamlanivimab due to its convenience, accessibility, and capabilities for
monitoring patients.
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1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic has resulted in over 247 million
cases of infection and over 5 million deaths [1]. This public health crisis has encouraged
prompt responses to discover new agents and therapies that may prevent or treat COVID-19
caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One
new treatment involves administering anti-SARS-CoV-2 antibodies to potentially reduce
viral load, improve symptoms, and prevent hospitalization [2,3]. In November 2020, bamlanivimab (LY-CoV555) was the first monoclonal antibody to be issued an emergency use
authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of
mild-to-moderate COVID-19 in non-hospitalized adult and pediatric patients at high risk
for progressing to severe disease and/or hospitalization [4]. Bamlanivimab is a recombinant
human immune globulin G kappa (IgG1κ) monoclonal antibody that is derived from convalescent plasma [4]. It neutralizes the surface spike glycoprotein of SARS-CoV-2, preventing
spike protein attachment to the human angiotensin-converting enzyme 2 (ACE2) receptor
and preventing entry of the virus into human cells [5]. Bamlanivimab is administered as a
one-time intravenous (IV) infusion over ≥60 min [4]. The phase 2 BLAZE-1 trial (n = 452)
reported that bamlanivimab, given at a dose of 2800 mg, significantly reduced the viral
load at day 11 (−0.53 difference 95% confidence interval (CI), −0.98 to −0.08; p = 0.02)
compared to placebo. Additionally, COVID-19-related hospitalizations at day 29 were 1.6%
in the bamlanivimab group vs. 6.3% in the placebo group [6].
Both the National Institute of Health and Infectious Diseases Society of America recommend the use of neutralizing antibodies for qualifying patients [7,8]. As bamlanivimab
is authorized for use in non-hospitalized patients, there are logistical concerns with how
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patients would receive this IV medication safely. Given the potential antigenicity and lack
of long-term data with monoclonal antibodies with EUA for COVID-19, bamlanivimab
should be infused in settings where health care providers who have the knowledge and
experience to treat severe infusion reactions can monitor patients for adverse effects and
infusion-related reactions for at least one hour post-infusion [4]. Traditional outpatient infusion centers are options for administering the infusion due to the established infrastructure
and resources, but there is concern regarding exposing high-risk patients (i.e., immunocompromised) who commonly frequent these centers to COVID-19 positive individuals.
Furthermore, at the beginning of the pandemic, these centers were actually identified as
potential sources of SARS-CoV-2 transmission, and other options were needed to decrease
this risk [9]. Additionally, an uptake of administering COVID-19 antibody treatment could
also cause an infusion center to become impacted.
The emergency department (ED) provides a unique setting for the implementation
of a monoclonal antibody infusion site for outpatient treatment. The benefits for using an
ED to infuse monoclonal antibodies are (1) more resources for medication preparation and
administration, (2) the ability to isolate patients, and (3) close monitoring by emergency
medicine-trained personnel. Additionally, patients presenting to the ED with COVID19 symptoms could be immediately screened for eligibility and receive the monoclonal
antibodies during the same visit. Institutions, like George Washington University and
Mount Sinai Medical Center, have reported successful implementation of ED administration
of COVID-19 antibody therapies [10,11].
In this paper, we describe the workflow and impact of administering IV monoclonal
antibodies in the ED of two large healthcare systems.
2. Materials and Methods
The implementation of a COVID-19 monoclonal antibody infusion program in the ED
was established at three hospitals in California: Providence Mission Hospital Mission Viejo
(Mission Viejo, CA, USA), Providence Mission Hospital Laguna Beach (Laguna Beach, CA,
USA), and the University of California, Irvine Medical Center (Orange, CA, USA).
2.1. Providence Mission Hospital Mission Viejo and Providence Mission Hospital Laguna Beach
Providence Mission Hospital Mission Viejo (MHMV) is a 504-bed acute care hospital in
Mission Viejo, California. Providence Mission Hospital Laguna Beach (MHLB) is a 189-bed
acute care hospital in Laguna Beach, California. Patients with mild-to-moderate COVID-19
symptoms could go about receiving bamlanivimab in the ED through one of two processes:
(1) by referral from an affiliated outpatient clinic or (2) by presenting directly to the ED,
either by walk-in or by ambulance. (Figure 1). Regardless of the setting, all patients were
screened using the bamlanivimab EUA inclusion criteria provided by the FDA. (Table 1).
If a patient presented to any affiliated outpatient clinic and was diagnosed with mildto-moderate COVID-19 not requiring hospitalization, the patient would be referred to
the nursing coordinator in charge of scheduling COVID-19 antibody infusion appointments. The nursing coordinator would determine the patient’s eligibility for receiving
bamlanivimab and then schedule an appointment for the patient to receive the monoclonal
antibody infusion in the ED at MHMV or MHLB, based on the patient’s preference. Initially,
only two patients per day were scheduled between 1200–1900, 7 days a week. The patient
would be instructed to present at their scheduled appointment time to the “tent” near the
entrance of the ED, where they would check in with the intake nurse. Conversely, patients
who presented directly to the ED to be evaluated for COVID-19-related symptoms would
be brought back to an isolated ED room or placed in the Respiratory Waiting Room if there
were no ED rooms available.
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Table 1. Bamlanivimab EUA Inclusion and Exclusion Criteria. The original bamlanivimab EUA
criteria only included adult patients (i.e., age ≥ 18 years old). In February 2021, the FDA updated the
inclusion criteria to include pediatric patients ≥12 years old.
Inclusion Criteria:

•

•

Adult ‡ and pediatric patients (12 years of age and older weighing at least 40 kg) with
positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to
severe COVID-19 and/or hospitalization.
High risk is defined as patients who meet at least one of the following criteria:
‡
‡
‡
‡
‡
‡
‡

Have a body mass index (BMI) ≥ 35 kg/m2 ;
Have chronic kidney disease;
Have diabetes;
Have immunosuppressive disease;
Are currently receiving immunosuppressive treatment;
Are ≥ 65 years of age;
Are ≥ 55 years of age AND have:
#
#
#

Cardiovascular disease, OR
Hypertension, OR
Chronic obstructive pulmonary disease/other chronic respiratory disease.

#

BMI ≥ 85th percentile for their age and gender based on CDC growth charts,
https://www.cdc.gov/growthcharts/clinical_charts.htm (accessed on 10
November, 2021).; OR
Sickle cell disease; OR
Congenital or acquired heart disease; OR
Neurodevelopmental disorders, for example, cerebral palsy; OR
A medical-related technological dependence, for example, tracheostomy,
gastrostomy, or positive pressure ventilation (not related to COVID-19); OR
Asthma, reactive airway, or other chronic respiratory disease that requires
daily medication for control.

Are 12–17 years of age AND have:

#
#
#
#
#
Exclusion Criteria

•

Patients who:
#
#
#
#

‡

#

Are hospitalized due to COVID-19;
Require oxygen therapy due to COVID-19;
Require an increase in baseline oxygen flow rate due to COVID-19 in those on
chronic oxygen therapy due to underlying non-COVID-19 related comorbidity;
Received bamlanivimab through clinical trial or compassionate use, or from another
EUA supply;
Has a contraindication to bamlanivimab (known hypersensitivity).

Denotes original EUA criteria approved in November 2020.

Regardless of if the patient was referred from the outpatient clinic or presented directly
to the ED with COVID-19 symptoms, they were re-evaluated by an ED provider (e.g.,
physician, physician assistant, or nurse practitioner). If eligible for monoclonal antibody
administration, the ED provider would provide the patient with a copy of the EUA fact
sheet, get consent to give bamlanivimab, document the patient’s eligibility in their progress
note, and then place an order for the bamlanivimab infusion in the patient’s electronic
health record (EHR). The bamlanivimab infusion was a standalone order (i.e., not a part
of an order set). Once the order was placed, the pharmacist would confirm the patient’s
eligibility, verify the order, and then print a label for the pharmacy technician to begin
preparing the medication in the IV room. Two bamlanivimab infusions were premade in the
morning to cover the two scheduled appointments. Any additional bamlanivimab orders
received outside of the two scheduled appointments were compounded once the label
printed. After the bamlanivimab was prepared, a pharmacy technician would hand-deliver
the medication to the ED nurse who was assigned to administer the antibody infusions for
that shift (the “Rapid Assessment Nurse”).

Healthcare 2022, 10, 42

Healthcare 2022, 10, x

4 of 10

Patients who were referred and had a scheduled appointment would receive the
infusion in the tent outside next to the ED, whereas those who presented directly to the ED
would receive their infusion wherever there was an available room—either in an assigned
ED room, the tent outside next to the ED, or if there were less than four infusions and the
patient presented outside of the tent operation times (1200–2330), the patient might need
to receive the infusion in the ED respiratory waiting room. Vitals and symptoms were
recorded prior to, during and after the infusion. Patients were observed for at least one
hour post-infusion. Supportive medications for any adverse effects were ordered as needed
at the provider’s discretion. If no complications arose, the patient would be discharged
from the ED and asked to follow up with their primary care physician in 2 days.
A list of patients who received a bamlanivimab infusion was kept on the hospital’s
secure server so that a nurse dedicated to conducting ED follow-up telephone calls would
be able to call the patient. Patients would receive a follow-up phone call within 1–5 days of
receiving their bamlanivimab infusion. During this telephone encounter, the nurse would
ask the patient questions related to the their COVID-19 symptoms, as well as questions
to determine any potential allergic reactions or adverse effects to the bamlanivimab. All
5 of 11
information provided during this telephone encounter was documented on a spreadsheet
for internal use.
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prioritized to receive bamlanivimab (Table 2).
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based on a point system, where patients were given a range of 1 to 4 points depending
on their age, gender, and concurrent comorbidities. Patients with the highest points were
prioritized to receive bamlanivimab (Table 2).
Table 2. Prioritization points for bamlanivimab administration. Priority for monoclonal antibody
administration was based on a point system, where patients were given a range of 1 to 4 points
depending on their age, gender, and concurrent comorbidities.
Age ≥ 80 years (4 points)
Age 65–79 years (2 points)
Age ≥ 50 years (1 point)
Solid organ transplant (3 points)
Body mass index (BMI) ≥ 35 kg/m2 (2 points)
Hematologic cancer (2 points)
Male sex (1 point)
Ethnicity non-white (1 point)
Chronic kidney disease (1 point)
Cirrhosis (1 point)
COPD (1 point)
Hypertension (1 point)
Heart disease (1 point)
Diabetes (1 point)
Recent (within 1 year) non-hematologic cancer (1 point)
Currently receiving immunosuppressive treatment (1 point)
Pregnancy (1 point)
Symptoms < 4 days (1 point)

After the ED physician reviewed the EUA fact sheet with the patient and received
consent to give the medication, the physician would input the order set into the EHR
and the order would be verified by a pharmacist. To ensure that the patient was eligible
and met ≥ 3 prioritization points (Table 2), the pharmacist was required to answer two
questions related to the patient’s eligibility, which were embedded into the EHR’s order
set (Figure 2). The bamlanivimab order set included the monoclonal antibody, along with
as needed orders for supportive medications, such as acetaminophen, ondansetron, and
epinephrine in case of an anaphylactic reaction (Figure 3).
After the bamlanivimab order set was verified, the inpatient pharmacy team would
prepare the medication. Once completed, the medication would be delivered to the unit.
The infusion nurse would follow the bamlanivimab administration protocol for proper
administration. Vital signs were taken at three different time points: within 30 min of
starting the infusion, 15 min after the start of infusion, and at the end of the infusion. After
the bamlanivimab was administered, the patient would be observed for at least 1 h for
hypersensitivity/infusion-related reactions. If no complications arose, the patient would
be discharged from the ED (Figure 3).
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After the bamlanivimab order set was verified, the inpatient pharmacy team would
prepare the medication. Once completed, the medication would be delivered to the unit.
The infusion nurse would follow the bamlanivimab administration protocol for proper
administration. Vital signs were taken at three different time points: within 30 min of
starting the infusion, 15 min after the start of infusion, and at the end of the infusion. After
the bamlanivimab was administered, the patient would be observed for at least 1 h for
hypersensitivity/infusion-related reactions. If no complications arose, the patient would
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3. Results
The bamlanivimab infusion workflow was implemented on 20 December 2020 at
Providence MHMV and MHLB locations. A total of 341 patients received bamlanivimab
infusion from 20 December 2020 to 20 March 2021. At UCIMC, the bamlanivimab infusion
workflow was implemented on 3 December 2020 and the first patient was treated on 4
December 2020. From 4 December 2020 to 15 April 2021, a total of 260 patients received
a bamlanivimab infusion. Collectively between the two health systems, 601 patients
received a bamlanivimab infusion. The mean age was 62 ± 16 years and about half were
male (n = 308, 51.2%). The most common high-risk eligibility criteria identified were
hypertension (56.6%), followed by diabetes (28.3%), immunosuppressive disease or on
immunosuppressive therapy (23.6%), and heart disease (23.5%) (Table 3).
Table 3. Patient demographics (n = 601).
Age, years (Mean ± SD)

62 ± 16

Male, n (%)

308 (51.2)

Hypertension, n (%)

340 (56.6)

Chronic kidney disease, n (%)

79 (13.1)

Immunosuppressive disease or on
immunosuppressive treatment, n (%)

142 (23.6)

Body mass index ≥ 35 kg/m2 , n (%)

109 (18.1)

Diabetes, n (%)

170 (28.3)

Asthma, n (%)

98 (16.3)

Chronic obstructive pulmonary disorder, n (%)

25 (4.2)

Sickle cell anemia, n (%)

9 (1.5)

Heart disease (congenital or acquired), n (%)

141 (23.5)

Neurodevelopmental disorders, n (%)

101 (16.8)

Medical-related device dependence *, n (%)

16 (2.7)

* including tracheostomy, gastronomy, positive pressure ventilation, etc.

Of the 601 patients who received a bamlanivimab infusion, 87 patients (14.5%) returned
to the hospital for COVID-19 symptoms within 10 days of bamlanivimab administration.
Of these patients, 43 (7.2%) were admitted for COVID-19 infection (Table 4).
Table 4. Patient results (n = 601).
Hospitalization for COVID-19 within 10 days of receiving bamlanivimab, n (%)

87 (14.5)

Admission for COVID-19 within 10 days of receiving bamlanivimab, n (%)

43 (7.2)

4. Discussion
A total of 601 patients received bamlanivimab infusion in the ED for mild-to-moderate
COVID-19 during the study period. Of the eighty-seven patients (14.5%) patients who
returned to the hospital for COVID-19-related illness, only 43 (7.2%) were admitted for
COVID-19 infection, resulting in a 92.8% hospitalization avoidance. However, these results should be considered with caution as they only include return visits and admissions
that occurred at one of the three study institutions. Additionally, given the retrospective
design of this report, there are limitations with the breadth of data collection. Nonetheless, our findings are similar to other prospective studies that have reported significant
reductions in ED visits or hospitalizations with bamlanivimab monotherapy as a secondary
outcome [6,12,13].
Despite the successful implementation of a bamlanivimab infusion program in the
ED, administration of bamlanivimab monotherapy was discontinued in March/April 2021
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due to the rise of resistant strains of COVID-19 to bamlanivimab. On 19 March 2021, the
California Department of Public Health recommended facilities and providers to stop
administering bamlanivimab monotherapy in California due to the rise of B.1.429/B.1.427
SARS-CoV2 variants [14]. Furthermore, on 16 April 2021, the FDA revoked bamlanivimab’s
EUA due to the updated BLAZE-1 phase 2 study results, which showed reduced efficacy of bamlanivimab monotherapy compared to placebo [12,13,15]. Consequently, both
institutions sought an alternative treatment option to replace bamlanivimab monotherapy.
Casirivimab and imdevimab are two recombinant human monoclonal antibodies
that bind to non-overlapping epitopes of the SARS-CoV-2 spike protein receptor binding
domain to inhibit the binding to the ACE2 receptor, thus, preventing entry of the virus [16].
The combination of casirivimab and imdevimab (REGN-COV2) was given EUA by the
FDA on 21 November 2020 based on the results from the R10933-10987-COV-2067 trial [17].
This study was a randomized, double-blind, placebo-controlled clinical trial conducted in
ambulatory adults with mild-to-moderate COVID-19 symptoms (n = 799) who were treated
with a single infusion of 2400 mg (1200 mg casirivimab/1200 mg imdevimab), 8000 mg
(4000 mg casirivimab/4000 mg imdevimab), or placebo [17]. As a result, both institutions
switched from using bamlanivimab to REGN-COV2. The same infusion protocol was kept
even after the medication switch since the ED proved to be an optimal location for other
similar infusion processes.
The combination of bamlanivimab and etesevimab is also another monoclonal antibody combination that was granted EUA by the FDA based on the updated results of
the BLAZE-1 study [18]. In phase 3 of the BLAZE-1 trial, ambulatory patients with mildto-moderate COVID-19 symptoms (n = 1035) who were treated with a single infusion of
2800 mg of bamlanivimab and 2800 mg of etesevimab (n = 518) had a lower incidence of
COVID-19-related hospitalization and death compared to placebo (n = 517) [19]. The combination of bamlanivimab and etesevimab also showed a greater reduction and accelerated
the decline in SARS-CoV-2 viral load compared to placebo [19].
A concern with the implementation of the infusion program in the ED is the strain
it could have on the department as a patient receiving antibodies takes up space and
staffing resources that could be used for other acute care patients. The American College of
Emergency Physicians published a statement supporting monoclonal antibody infusions in
the ED as long as hospitals can ensure that there is adequate resources to care for emergency
patients [20]. At UCIMC, we did not notice any strains on the department as the process
was streamlined and the patients did not require intensive care. Furthermore, extra space
was added to help mediate a potential impacted ED. For example, the implementation
of outdoor mobile tents to triage patients in the ED helped create more room. On the
other hand, at Providence MHMV, though there was already a tent set up outside the
ED for isolation of potential COVID-19 patients, the ED nursing and pharmacy staff
experienced a strain with the additional time consumption and use of resources used for the
implementation of an infusion program. To work through these challenges, administrators
from both departments and key stakeholders should work together to develop a workflow
that works for the institution. For example, the maximum of two monoclonal antibody
infusion appointments per day was initiated post-implementation of the infusion program
to address concerns of the staff involved.
Outpatient infusion centers could be utilized as an additional site of monoclonal
antibody administration to alleviate strain in the ED, but many patients who frequent the
outpatient infusion center are immunocompromised and could be put at higher risk if they
come in contact with patients diagnosed with COVID-19. Additionally, scheduling patients
is a major concern with infusion centers, and patients requiring monoclonal antibody
administration could have delay of care because of this. Many patients also presented to
the ED directly with a diagnosis of mild-to-moderate COVID-19 and referring them to an
outpatient infusion center could also cause a delay of care.
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5. Conclusions
This paper describes the successful implementation of two different bamlanivimab infusion programs in the EDs of two large health systems. Despite having to rapidly develop
the workflows in a short period of time after the bamlanivimab EUA was approved, there
were no major workflow issues that occurred, regardless of whether patients presented
directly to the ED or were referred/scheduled for a bamlanivimab appointment. Given
the vulnerability of patients in infusion centers and the logistical and safety considerations
of monoclonal antibody IV administration, the ED is an optimal setting due to its patient
accessibility, capacity to isolate and monitor patients, and emergency medicine-trained
personnel who have the expertise to manage severe allergic and infusion-related reactions.
The methods described in this paper could be utilized for future administrations of
monoclonal antibodies/infusions for COVID-19 or other disease states in the ED.
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